Academic Journal

Gut-confined fullerene reprograms lactate metabolism to Rescue hypoxia-induced exercise intolerance.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Gut-confined fullerene reprograms lactate metabolism to Rescue hypoxia-induced exercise intolerance.
Συγγραφείς: Chen S; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Pan Y; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China., Liu M; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Liu C; Translational Medicine Research Center, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing, 100853, China., Xu Y; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Ma J; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Li J; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China., Wang X; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Yang L; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Wang Y; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China., Li B; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China., Wang Z; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China., Zhang Y; Beijing FULLCAN Biotechnology Co., Beijing 100085, China., Shen H; Beijing FULLCAN Biotechnology Co., Beijing 100085, China., Wulan Q; College of Chemistry and Life Sciences, Chifeng University, Chifeng 024000, China., Li J; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China. Electronic address: lijie24@iccas.ac.cn., Wang C; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China. Electronic address: crwang@iccas.ac.cn., Bai C; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing, 100049, China. Electronic address: clbai@cas.cn.
Πηγή: Biomaterials [Biomaterials] 2026 Aug; Vol. 331, pp. 124075. Date of Electronic Publication: 2026 Feb 11.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8100316 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5905 (Electronic) Linking ISSN: 01429612 NLM ISO Abbreviation: Biomaterials Subsets: MEDLINE
Imprint Name(s): Publication: <1995-> : Amsterdam : Elsevier Science
Original Publication: [Guilford, England] : IPC Science and Technology Press, 1980-
Ιατρικοί όροι (MeSH): Fullerenes*/administration & dosage , Fullerenes*/pharmacology , Fullerenes*/therapeutic use , Hypoxia*/metabolism , Hypoxia*/complications , Lactic Acid*/metabolism , Exercise Tolerance*/drug effects , Gastrointestinal Tract*/metabolism , Gastrointestinal Tract*/drug effects, Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Reactive Oxygen Species/metabolism ; Animals ; Mice, Inbred C57BL ; Mice
Περίληψη: Chronic hypoxia-induced exercise intolerance, a hallmark of high-altitude deterioration (HADT), lacks safe long-term therapies. Here, we develop an orally administered fullerene (C60) suspension that acts exclusively within the gastrointestinal tract due to negligible systemic absorption. Under chronic hypoxia, fullerene significantly reduced systemic lactate and enhanced exercise endurance without affecting muscle, hepatic, or renal lactate metabolism. Mechanistically, fullerene locally quenched reactive oxygen species (ROS) in intestinal epithelial cells, destabilizing hypoxia-inducible factor-1α (HIF-1α) and suppressing glycolysis. This reduced endogenous gut lactate production, alleviating lactate-mediated inhibition of muscle function. Crucially, fullerene concurrently preserved intestinal barrier integrity and mitigated hypoxia-induced damage. By confining therapeutic action to the gut-minimizing systemic exposure-this "local-to-systemic" strategy offers a fundamentally new solution for HADT with superior safety for chronic use, demonstrating broader potential for hypoxia-associated diseases.
(Copyright © 2026. Published by Elsevier Ltd.)
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Contributed Indexing: Keywords: Chronic mountain sickness; Exercise tolerance; Fullerene; Lactate metabolism
Substance Nomenclature: 0 (Fullerenes)
33X04XA5AT (Lactic Acid)
0 (Hypoxia-Inducible Factor 1, alpha Subunit)
0 (Reactive Oxygen Species)
Entry Date(s): Date Created: 20260224 Date Completed: 20260708 Latest Revision: 20260708
Update Code: 20260708
DOI: 10.1016/j.biomaterials.2026.124075
PMID: 41734653
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1878-5905
DOI:10.1016/j.biomaterials.2026.124075